Cargando…

Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy

PURPOSE: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Freiberg, Florentina Joyce, Matlach, Juliane, Grehn, Franz, Karl, Sabine, Klink, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693864/
https://www.ncbi.nlm.nih.gov/pubmed/23814458
http://dx.doi.org/10.2147/OPTH.S41750
_version_ 1782274760798896128
author Freiberg, Florentina Joyce
Matlach, Juliane
Grehn, Franz
Karl, Sabine
Klink, Thomas
author_facet Freiberg, Florentina Joyce
Matlach, Juliane
Grehn, Franz
Karl, Sabine
Klink, Thomas
author_sort Freiberg, Florentina Joyce
collection PubMed
description PURPOSE: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb morphology, postoperative medications, and complications was evaluated. METHODS: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed exclusively by one experienced glaucoma specialist using a standardized technique. Patients in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 received 5-FU and subconjunctival injection of bevacizumab. RESULTS: Group 1 had 6.4 ± 3.3 (0–15) (mean ± standard deviation and range, respectively) 5-FU injections. Group 2 had 4.0 ± 2.8 (0–12) (mean ± standard deviation and range, respectively) 5-FU injections. The added injection of bevacizumab significantly reduced the mean number of 5-FU injections by 2.4 ± 3.08 (P ≤ 0.005). There was no significantly lower IOP in group 2 when compared to group 1. A significant reduction in vascularization and in cork screw vessels could be found in both groups (P < 0.0001, 7 days to last 5-FU), yet there was no difference between the two groups at the last follow-up. Postoperative complications were significantly higher for both groups when more 5-FU injections were applied. (P = 0.008). No significant difference in best corrected visual acuity (P = 0.852) and visual field testing (P = 0.610) between preoperative to last follow-up could be found between the two groups. CONCLUSION: The postoperative injection of bevacizumab reduced the number of subconjunctival 5-FU injections significantly by 2.4 injections. A significant difference in postoperative IOP reduction, bleb morphology, and postoperative medication was not detected.
format Online
Article
Text
id pubmed-3693864
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36938642013-06-30 Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy Freiberg, Florentina Joyce Matlach, Juliane Grehn, Franz Karl, Sabine Klink, Thomas Clin Ophthalmol Original Research PURPOSE: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb morphology, postoperative medications, and complications was evaluated. METHODS: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed exclusively by one experienced glaucoma specialist using a standardized technique. Patients in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 received 5-FU and subconjunctival injection of bevacizumab. RESULTS: Group 1 had 6.4 ± 3.3 (0–15) (mean ± standard deviation and range, respectively) 5-FU injections. Group 2 had 4.0 ± 2.8 (0–12) (mean ± standard deviation and range, respectively) 5-FU injections. The added injection of bevacizumab significantly reduced the mean number of 5-FU injections by 2.4 ± 3.08 (P ≤ 0.005). There was no significantly lower IOP in group 2 when compared to group 1. A significant reduction in vascularization and in cork screw vessels could be found in both groups (P < 0.0001, 7 days to last 5-FU), yet there was no difference between the two groups at the last follow-up. Postoperative complications were significantly higher for both groups when more 5-FU injections were applied. (P = 0.008). No significant difference in best corrected visual acuity (P = 0.852) and visual field testing (P = 0.610) between preoperative to last follow-up could be found between the two groups. CONCLUSION: The postoperative injection of bevacizumab reduced the number of subconjunctival 5-FU injections significantly by 2.4 injections. A significant difference in postoperative IOP reduction, bleb morphology, and postoperative medication was not detected. Dove Medical Press 2013 2013-06-20 /pmc/articles/PMC3693864/ /pubmed/23814458 http://dx.doi.org/10.2147/OPTH.S41750 Text en © 2013 Freiberg et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Freiberg, Florentina Joyce
Matlach, Juliane
Grehn, Franz
Karl, Sabine
Klink, Thomas
Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
title Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
title_full Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
title_fullStr Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
title_full_unstemmed Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
title_short Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
title_sort postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693864/
https://www.ncbi.nlm.nih.gov/pubmed/23814458
http://dx.doi.org/10.2147/OPTH.S41750
work_keys_str_mv AT freibergflorentinajoyce postoperativesubconjunctivalbevacizumabinjectionasanadjunctto5fluorouracilinthemanagementofscarringaftertrabeculectomy
AT matlachjuliane postoperativesubconjunctivalbevacizumabinjectionasanadjunctto5fluorouracilinthemanagementofscarringaftertrabeculectomy
AT grehnfranz postoperativesubconjunctivalbevacizumabinjectionasanadjunctto5fluorouracilinthemanagementofscarringaftertrabeculectomy
AT karlsabine postoperativesubconjunctivalbevacizumabinjectionasanadjunctto5fluorouracilinthemanagementofscarringaftertrabeculectomy
AT klinkthomas postoperativesubconjunctivalbevacizumabinjectionasanadjunctto5fluorouracilinthemanagementofscarringaftertrabeculectomy